Justin Lake

Joel clarified the phasing: third-quarter operating income is expected below the fourth, largely driven by IKC timing.

Joel declined to give specific quarterly mortality numbers but said the improvement is sustained across several quarters and drove the quarter's volume upside.

CFO clarified the $70M cyber impact: $25M volume (largely permanent census loss) and $45M RPT. The $45M RPT recovery in 2026 is roughly offset by the $40M premium tax credit headwind. Aged claims resolution was normal in aggregate for 2025, just concentrated in Q4.

CEO described improvement as coming from a portfolio of clinical interventions rather than any single driver. Three IKC dimensions: volume (flat), care model/G&A costs (flat), and shared savings (improved through better contracting and clinical performance). Comfortable guiding +$20M IKC OI growth for 2026.

CFO specified Q4 absolute treatment volume growth of 20-30bps year-over-year, clarifying this is total volume, not per-day or non-acquired growth.

CFO corrected to ~$8 sequential RPT improvement. Of the $50M RPT pickup (~$7/treatment), more than half is from aged claims resolution which is harder to predict and more variable than typical rate increases.

RPT ex-binders lowered from 3% to 2.25% for the year, entirely driven by the cyber incident's Q2 impact of $40-$50 million.

CFO quantified non-acquired growth at roughly negative 50bps, with volume expected to be worse in Q3 and better in Q4 due to prior-year census shape comparisons.

CFO attributed quarterly NCI variance to Change Healthcare collection timing dynamics, confirming no underlying trend change in NCI as a percentage of US dialysis OI.

CFO noted $50M from collections annualization, commercial mix at 11% with slight gains expected, and exchange patients at 3% of population vs 2% pre-enhanced premium tax credits.

Bobby Hunter said Medicare margins should land near the top end of the 2%-4% range, crediting recovery actions on medical trend and cost management.

Management cited Q3 improvement and full-year Medicaid results moderately better than forecast, but did not say whether the business is at break even.

Dan Kueter quantified drivers (IDR, coding intensity, specialty pharmacy) and conceded margin recovery extends past 2027; Medicaid answered with the -1% to -1.7% range reaffirmed.

Wayne confirmed $1.3B is the clean comparable to $1.575B guide, removing noncash accounting of loss contract and asset dispositions. Noted all 4 segments exceeded internal plan. Krista said PYD was partially favorable to expectations but reflected intentional Q4 actions, with early-year prudence warranted.

Nelson acknowledged Q4 slightly disappointing but reflective of restructuring actions and one-time items now behind them. Excluding restructuring and Optum Financial move, adjusted earnings approximately $1.5 billion as new baseline. Cited strategic clarity, network narrowing of nearly 20%, risk membership streamlined by 15%, and nearly 100% of employee groups on three EMRs as confidence drivers.

Noel confirmed 2026 commercial margins probably still 150 basis points below the 7% low end of target range. Pricing received well in marketplace. Long-term 7-9% range attainable with current trajectory.

Rex confirmed second half run rate assessment. Hunter said 2025 MA margins likely in low end of new 2-4% range at 2-2.5%. For 2026 expects margin expansion to 2.5-3% from benefit cuts, plan reductions, and trend pricing. Midpoint of range targeted by 2027. 80% of premium revenues reprice January 1.

Noel broke down trend drivers: care activity (units consumed) is about one-third of total Medicare trend. Q1 2025 showed 2x increase in units consumed versus expected. Making assumption this persists through 2025 and into 2026 for pricing. Unit prices behaved as expected.

Rex sized non-run-rate revenue impacts at 80-90bps including group MA refunds from strong performance. Not a surprise in recent months but was not in original year-ago outlook. Bobby Hunter detailed AEP results: balanced growth, strong HMO uptake, 3x returning members.

Justin pushed to quantify the specialty-vs-PBS earnings shift; Ann and Brian gave qualitative offsetting dynamics (Q2 outperformance given back via lower H2 GLP-1) but no specific sizing. Partial.

Ann explained NCI increase was from a new JV with a large client where most economics are passed back despite majority ownership. Structure is part of client retention, fully contemplated in guidance.

Brian confirmed FTC agreement won't impact 2027 financial outlook. Investment costs for rebate-free model continue in 2027 but long-term growth algorithm intact. No expected changes to PBS revenue recognition under new fee-based model.

Brian provided detailed framework: 2025 Evernorth ~$7.2B split equally (~$3.6B each). Specialty & Care to grow at high end. Aggregate Evernorth to decline slightly. Large client renewals represent more than half of PBS decline; investment spend less than half.

David confirmed elevated AI-driven billing sophistication but noted CI's own AI capabilities help counteract. Brian said stop-loss premiums grew 13% with sold rate increases after January higher than January increases, and sophisticated billing does not have outsized impact on stop-loss.

Brian confirmed tracking to plan, revised cost structure incorporated into later 2025 renewals while preserving retention. Ann noted elevated trends consistent with expectations, some surgical moderation.

Brian quantified $6.7B stop loss premium, low-90s MCR for FY2024, mid-single-digit miss. Individual stop loss more tilted than aggregate. Balance of Cigna Healthcare ran in line.

Asher walked the bridge line by line, roughly $250 million of rolling margin plus $50 million of other deducts, reconciling $481 million down to the $180 million guidance delta.

Sarah confirmed slight receivable position is across the whole book since risk adjustment is metal-tier agnostic, not the full amount data suggests. Did not book full potential with range wrapping around and exceeding original 4% target. Medicare not reflecting continued outperformance in Q2-Q4 for either MA or PDP but fundamental drivers suggest both segment margins come in slightly better than current guidance.

Sarah explained 2025 trend ran mid-6% while 2026 mid-4% is a net trend assumption reflecting elevated baseline jump-off from 94.9% Q2, aggressive back-half trend bending, and bankable Q3/Q4 actions not effective until 2026. Rates came in at mid-4s for 2026 versus 5.5% composite in 2025, with program changes serving as proxy for rate in some states.

Sarah noted low-cost silver position dropped from 55% to 42%, reflecting margin-over-membership focus. Drew said PDP running 3%+ pretax in 2025 but would guide to something less for initial 2026 guidance.

Sarah confirmed expectation of 2026 margin improvement in all 3 lines. Detailed Q2 miss concentration: behavioral health 50%, home health 30%, drugs remainder. Florida alone drove 40bps of Q2 HBR pressure.

Drew confirmed excellent consistency between year-end estimates and Q1 actuals. Not yet booking 2025 risk adjustment receivable for new members until June/July data.

Drew confirmed PYD included CSR settlement of over $200M. Sarah noted expected rate actions didn't materialize by year-end but may benefit 2025.

Brian confirmed only dilution-offset is assumed in 2027; Prem argued PCW growth is durable via CostVantage pricing, above-market script growth and operating leverage across 9,000 stores.

Management directly addressed rate adequacy and reaffirmed confidence in reaching target margins by 2028, citing disciplined strategy and leading Star scores.

Joyner confirmed commitment to MA margin recovery unchanged despite disappointing rate notice. Nelson emphasized strong Stars position carried into 2027 and successful group MA repricing.

Shah detailed 28.9% script share, 400bps immunization market share gain. Newman noted PCW guide now at +3% growth, 8% swing from initial -5% expectation.

Joyner declined to provide 2026 color, deferring to year-end update. Did not address the specific questions on pharmacy sustainability or VBC improvement.

Cowhey provided granular trend detail: inpatient consistent with full year 2024, outpatient modestly favorable, medical pharmacy stubbornly high. Group MA in-patient remains pressured.

Cowhey provided detail on Q4 trends by segment but declined to quantify specific 2025 trend assumptions, saying it was too early given membership mix changes.

Mark addressed acuity (no new stepwise reset, gap between leavers and stayers narrowing) but did not size the exits against the $57 billion Medicaid run rate.

Mark confirmed comfort with high single-digit membership decline guidance, expecting to finish at higher end of range. Timing modestly more favorable than originally assumed, with greater pressure expected in H2.

Mark detailed Q4 margins: Medicaid slightly better from favorable PYD and modest retroactive rates; Medicare in line including IRA Part D seasonality; commercial group consistent; ACA slightly better than prudent outlook. 2026 framework: Medicaid pressure offset by MA improvement and better ACA. Flu headwind of 20bps embedded in Q1 2026.

Mark confirmed margin deterioration through the year. Noted intensified care management in LTSS, behavioral health, and specialty pharmacy showing measurable improvement. Gail clarified the 125bp decline assumes entering 2026 at the level exiting 2025.

Mark declined specific margins but disclosed ACA operating margin declining high single-digit percent YoY. Gail outlined 2026 opportunities across pricing discipline, Carelon growth, and Medicaid rate catch-up.

Mark confirmed BER decreased Q4 to Q1 more than typical, driven by workday dynamics and Part D seasonality. Medicaid trends elevated but decelerating. Recovery remains a first-half/second-half story.

Mark detailed >60% of EPS in H1, with >50% of H1 in Q1. Health Benefits margin declining 25-50bps from cycling non-recurring benefits and Medicare mix shift, not core deterioration.